Pharmacokinetics and safety of trovafloxacin in healthy male volunteers following administration of single intravenous doses of the prodrug, alatrofloxacin

Journal of Antimicrobial Chemotherapy

Volumn 39, Issue SUPPL. B, 1997, Pages 75-80

  Vincent, J ^a   Venitz, J ^b   Teng, R ^a   Baris, B A ^a   Willavize, S A ^a   Polzer, R J ^a   Friedman, H L ^a  

^a PFIZER INC   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALATROFLOXACIN; PRODRUG; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TROVAFLOXACIN; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG URINE LEVEL; ERYTHEMA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; ULTRAVIOLET SPECTROSCOPY;

EID: 0030793087     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/39.suppl_2.75     Document Type: Article

References (26)

1. Neu, H. C. & Chin, N.-X. (1994). In vitro activity of the new fluoroquinolone CP-99,219. Antimicrobial Agents and Chemotherapy 38, 2615-22.
2. Neu, H. C. (1992). An update on fluoroquinolones. Current Opinion in Infectious Diseases 5, 755-63.
3. Hooper, D. C. & Wolfson, J. S. (1991). Fluoroquinolone antimicrobial agents. New England Journal of Medicine 324, 384-94.
4. Guay, D. R. P. (1992). The role of the fluoroquinolones. Pharmacotherapy 12, 71S-85S.
5. Fitton, A. (1992). The quinolones: an overview of their pharmacology. Clinical Pharmacokinetics 22, Suppl. 1, 1-11.
6. Gooding, B. B. & Jones, R. N. (1993). In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone. Antimicrobial Agents and Chemotherapy 37, 349-53.
7. Eliopoulos, G. M., Klimm, K., Eliopoulos, C. T., Ferraro, M. J. & Moellering, R. C. (1993). In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of Gram-positive bacteria. Antimicrobial Agents and Chemotherapy 37, 366-70.
8. Spangler, S. K., Jacobs, M. R. & Appelbaum, P. C. (1994). Activity of CP 99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobes. Antimicrobial Agents and Chemotherapy 38, 2471-6.
9. Girard, A. E., Faiella, J. A., Cimochowski, C. R. & Brighty, K. E. (1993). In vivo oral activity of CP-99,219 in models of acute and localized infection. In Program and Abstracts of the Thirty-Third Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, 1993, Abstract 1510, p. 395. American Society for Microbiology, Washington, DC.
10. Teng, R., Harris, S. C., Nix, D. E., Schentag, J. J., Foulds, G. & Liston, T. E. (1995). Pharmacokinetics and safety of trovafloxacin (CP-99,219), a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers. Journal of Antimicrobial Chemotherapy 36, 385-94.
11. Goormans, E., Dalhoff, A., Kazzaz, B. & Branolte, J. (1986). Penetration of ciprofloxacin into gynecological tissues following oral and intravenous administration. Chemotherapy (Basle) 32, 7-17.
12. Borner, K., Lode, H., Höffken, G., Sievers, B., Olschewski, P., Lebahn, H. et al. (1989). Monitoring of ofloxacin after intravenous and oral administration. Reviews of Infectious Diseases 11, Suppl. 5, S1009.
13. Trenholme, G. M., Schmitt, B. A., Spear, J., Gvazdinskas, L. C. & Levin, S. (1989). Randomized study of intravenous/oral ciprofloxacin versus ceftazidime in the treatment of hospital and nursing home patients with lower respiratory tract infections. American Journal of Medicine 87, Suppl. 5A, 116S-8S.
14. Gelfand, M. S., Simmons, B. P., Craft, R. B., Grogan, J. & Amarshi N. (1993). A sequential study of intravenous and oral fleroxacin in the treatment of complicated urinary tract infection. American Journal of Medicine 94, Suppl. 3A, 126-30S.
15. Teng, R., Vincent, J., Baris, B. & Willavize, S. A. (1995). Pharmacokinetics of single and multiple intravenous doses of alatrofloxacin, the prodrug of CP-99,219, in healthy male volunteers. In Program and Abstracts of the Thirty-Fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA 1995. Abstract F240, p. 155. American Society for Microbiology, Washington DC.
16. Teng, R., Tensfeldt, T. G., Liston, T. E. & Foulds, G. (1996). Determination of trovafloxacin, a new quinolone antibiotic, in bio logical samples by reversed-phase high-performance liquid chromatography. Journal of Chromatography B: Biomedical Applications 675, 53-9.
17. Benet, L. Z. & Galeazzi, R. L. (1979). Noncompartmental determination of the steady-state volume of distribution. Journal of Pharmaceutical Sciences 68, 1071-4.
18. Zürcher, J., Jaehde, U., Gottschalk, B., Sörget, F., Naber, K., Sigl, G. et al. (1989). Effect of dose on bioavailability, pharmacokinetics, and metabolism of pefloxacin following administration of single and multiple doses. Reviews of Infectious Diseases 11, Suppl. 5, S1014-5.
19. Schentag, J. J., Nix, D. E., Stroshane, R. M., Cook, J. A., Brown, R. R. & Silverman, M. H. (1989). Pharmacokinetics of amifloxacin after oral and intravenous administration. Reviews of Infectious Diseases 11, Suppl. 5, S1020.
20. Mant, T. G. K., Morrison, P. J., Norman, G. T. & Robinson, J. (1989). Multiple-dose pharmacokinetics and tolerance of lomefloxacin. Reviews of Infectious Diseases 11, Suppl. 5, S1021.
21. Bailey, R. R., Lynn, K. L., Robson, R. A., Peddie, B. A. & Smith, A. (1992). Comparison of ciprofloxacin with netilmicin for the treatment of acute pyelonephritis. New Zealand Medical Journal 105, 102-3.
22. Quintiliani, R., Cooper, B. W., Briceland, L. L. & Nightingale, C. H. (1987). Economic impact of streamlining antibiotic administration. American Journal of Medicine 82, Suppl. 4A, 391-4.
23. Ehrenkranz, N. J. (1989). Containing costs of antimicrobials in the hospital: a critical evaluation. American Journal of Infection Control 17, 300-10.
24. Cockburn, J., Gibberd, R. W., Reid, A. L. & Sanson-Fisher, R. W. (1987). Determinants of non-compliance with short term antibiotic regimens. British Medical Journal 295, 814-8.
25. Tsubakihara, Y., Itoh, T., Kitamura, E., Okada, N., Nakanishi, I. & lida, N. (1989). Pharmacokinetics of ofloxacin in patients with severe chronic renal failure. Reviews of Infectious Diseases 11, Suppl. 5, S1006-7.
26. Stuck, A. E., Frey, F. J., Heizmann, P., Brandt, R. & Weidekamm, E. (1989). Pharmacokinetics and metabolism of intravenous and oral fleroxacin in subjects with normal and impaired renal function and in patients on continuous ambulatory peritoneal dialysis. Antimicrobial Agents and Chemotherapy 33, 373-81.